A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria

Trial Profile

A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Tafenoquine (Primary) ; Chloroquine; Primaquine
  • Indications Malaria
  • Focus Registrational; Therapeutic Use
  • Acronyms GATHER
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jun 2017 Full results will be submitted for publication in peer-reviewed journals, as reported in a GlaxoSmithKline Media Release.
    • 12 Jun 2017 Results from this trial presented at the International Conference on Plasmodium vivax Research (ICPVR) 2017, as reported in a GlaxoSmithKline Media Release.
    • 12 Jun 2017 Results published in the GlaxoSmithKline Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top